JP2021523946A5 - - Google Patents

Info

Publication number
JP2021523946A5
JP2021523946A5 JP2021514457A JP2021514457A JP2021523946A5 JP 2021523946 A5 JP2021523946 A5 JP 2021523946A5 JP 2021514457 A JP2021514457 A JP 2021514457A JP 2021514457 A JP2021514457 A JP 2021514457A JP 2021523946 A5 JP2021523946 A5 JP 2021523946A5
Authority
JP
Japan
Prior art keywords
lck
amino acid
composition according
composition
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021514457A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523946A (ja
JP7386852B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2019/050463 external-priority patent/WO2019218016A1/en
Publication of JP2021523946A publication Critical patent/JP2021523946A/ja
Publication of JP2021523946A5 publication Critical patent/JP2021523946A5/ja
Application granted granted Critical
Publication of JP7386852B2 publication Critical patent/JP7386852B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021514457A 2018-05-15 2019-05-15 ペプチド活性化剤 Active JP7386852B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2018901673 2018-05-15
AU2018901673A AU2018901673A0 (en) 2018-05-15 Peptide Activating Agent
PCT/AU2019/050463 WO2019218016A1 (en) 2018-05-15 2019-05-15 Peptide activating agent

Publications (3)

Publication Number Publication Date
JP2021523946A JP2021523946A (ja) 2021-09-09
JP2021523946A5 true JP2021523946A5 (enExample) 2022-05-24
JP7386852B2 JP7386852B2 (ja) 2023-11-27

Family

ID=68539135

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021514457A Active JP7386852B2 (ja) 2018-05-15 2019-05-15 ペプチド活性化剤

Country Status (8)

Country Link
US (2) US11912789B2 (enExample)
EP (1) EP3794014A4 (enExample)
JP (1) JP7386852B2 (enExample)
KR (1) KR102918269B1 (enExample)
CN (1) CN112399970B (enExample)
AU (1) AU2019268412B2 (enExample)
CA (1) CA3100074A1 (enExample)
WO (1) WO2019218016A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111518187B (zh) * 2020-04-16 2022-05-10 中国农业科学院饲料研究所 抗菌肽dn6nh2及其应用
WO2023019323A1 (en) * 2021-08-20 2023-02-23 Interk Peptide Therapeutics Limited Compositions and methods for treating autoimmunity, including autoimmunity associated with cancer and cancer therapy

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1226552B (it) 1988-07-29 1991-01-24 Ellem Ind Farmaceutica Peptidi immunostimolanti.
AU2005204275B2 (en) * 1999-06-28 2008-10-16 Inter-K Pty Limited A method of modulating integrin mediated cellular activity and agents useful for same
AU2007231835A1 (en) * 2000-12-22 2007-11-29 Inter-K Pty Limited Screening assay for an inhibitor of MAP kinase?integrin binding
US20050187147A1 (en) 2003-09-22 2005-08-25 Newman Michael J. Compositions and methods for increasing drug efficiency
WO2005030258A2 (en) * 2003-09-22 2005-04-07 Acidophil Llc Small molecule compositions and methods for increasing drug efficiency using compositions thereof
DK2185698T3 (en) 2007-08-07 2015-07-27 Purdue Research Foundation Kinase Inhibitors and Uses thereof
KR101294514B1 (ko) 2007-09-18 2013-08-12 가부시키가이샤 그린 펩티드 Ｃｔｌ 유도제 조성물
PT2119726E (pt) 2008-05-14 2015-03-30 Immatics Biotechnologies Gmbh Novos e poderosos peptídeos para mhc classe ii derivados de survinina e neurocano
US9327008B2 (en) 2008-12-10 2016-05-03 Purdue Research Foundation Cell-permeant peptide-based inhibitor of kinases
AU2010215086A1 (en) * 2009-02-23 2011-09-08 Inter-K Pty Limited Inhibition of multiple cell activation pathways
US20120277161A1 (en) * 2009-02-23 2012-11-01 Inter-K Pty Limited Inhibition of multiple cell activation pathways
US20110200560A1 (en) * 2009-05-26 2011-08-18 Massachusetts Institute Of Technology Non-ionic self-assembling peptides and uses thereof
US9580474B2 (en) 2010-09-08 2017-02-28 The Johns Hopkins University Polyionic papilloma virus-like particle (VLP) vaccines
RU2623161C2 (ru) * 2011-04-15 2017-06-22 Компуджен Лтд. Полипептиды и полинуклеотиды и их применение для лечения иммунологических нарушений и рака
WO2012174412A2 (en) 2011-06-16 2012-12-20 La Jolla Institute For Allergy And Immunology Compositions targeting pkc-theta and uses and methods of treating pkc-theta pathologies, adverse immune responses and diseases
CN104271590B (zh) 2012-01-24 2018-06-05 Inter-K私人有限公司 用于癌治疗的肽剂
EP3442991A4 (en) * 2016-04-15 2019-11-20 RA Pharmaceuticals, Inc. RAS-BINDING PEPTIDES AND METHODS OF USE
CN112368293A (zh) * 2018-05-15 2021-02-12 英特肽治疗有限公司 活化剂

Similar Documents

Publication Publication Date Title
JP7360419B2 (ja) 安定化抗微生物性ペプチド
JP2021523945A5 (enExample)
JP2014521684A5 (enExample)
JP2013500990A5 (enExample)
JP2008514586A5 (enExample)
CA2112907C (en) Peptide which abrogates tnf and/or lps toxicity
JP2005526833A5 (enExample)
RU2016110153A (ru) Новые пептиды и их аналоги для применения при лечении мукозита полости рта
IL316406A (en) Lipid-modified relaxin B peptide chains and their medical use
CN106232616A (zh) 两亲性合成抗菌肽、其药物组合物及其用途
US20250215054A1 (en) Compositions and methods for treatment of fungal infections
JP2009534451A5 (enExample)
JPWO2022202816A5 (enExample)
JP2014519514A5 (enExample)
JP2017500849A5 (enExample)
JP2006523608A5 (enExample)
US11299518B2 (en) Fusion respiratory syncytial virus inhibitors and use thereof
CN1133048A (zh) 由c-活性蛋白质片段衍生的寡肽
EP2990415B1 (en) Cyclic beta defensins analogs for the treatment of infections
JP2015514771A5 (enExample)
JPWO2018038168A1 (ja) ヘマグルチニン結合ペプチド、および、これを含むインフルエンザウイルス感染症の予防・治療薬
US12012440B2 (en) Compositions and methods for treatment of fungal infections
JP2009515933A (ja) インフルエンザにおけるインターフェロン
WO1997048725A1 (en) Novel peptides for prevention and treatment of infection
JP2014198711A (ja) Ｃｔ阻害４価ペプチドおよびコレラ治療薬